Axogen, Inc. — Director's Dealing 2013

Feb 28, 2013

SEC Form 3/A — Form 3/A

Issuer: AxoGen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2013-02-28

Reporting Person: Gold Mark Stephen (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$0.27	2017-07-25	Common Stock (3727)		Direct
Employee Stock Option (right to buy)	$0.27	2021-02-24	Common Stock (15019)		Direct
Stock Option (right to buy)	$1.07	2021-09-29	Common Stock (869)		Direct

Footnotes

F1: All of these options have vested.

F2: Amended to correct mistake in option exercise price after appropriate application of conversion ratio as explained in footnotes.

F3: Pursuant to an Agreement and Plan of Merger, dated as of May 31, 2011, by and among LecTec Corporation ("LecTec"), Nerve Merger Sub Corp., a subsidiary of LecTec ("Merger Sub"), and AxoGen Corporation ("AC"), which the parties amended on June 30, 2011 and August 9, 2011 (as amended, the "Merger Agreement"), Merger Sub merged with and into AC, with AC continuing after the merger as the surviving corporation and a wholly owned subsidiary of LecTec (the "Merger"). The Merger was completed on September 30, 2011, and LecTec was renamed AxoGen, Inc. ("AxoGen"). In connection with the Merger, each share of AC common stock converted into 0.03727336 share of LecTec common stock at the effective time of the Merger. In connection with the Merger, each option to purchase shares of AC common stock was converted tor an option to purchase 0.03727336 of a share of AxoGen common stock.

F4: These options vest annually over three years beginning with the Exercisable Date reported herein.

F5: Corrected to remove Stock Options to purchase 5,964, 4,864 and 4,210 shares at $.25, $.25 and $1.00 per share, respectively, and provide correct Stock Option.